Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2021-05-11 Director's Dealing
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 100% confidence The document is titled 'Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons'. It explicitly references Article 19 of Regulation No. 596/2014 (Market Abuse Regulation), which is the standard regulatory requirement for reporting insider/director dealings. While the text mentions an attachment, the core purpose of the filing is to disclose these specific transactions. Therefore, it falls under the 'Director's Dealing' category.
2021-05-11 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, the impact on total share capital, and the regulatory compliance with the Danish Capital Markets Act. This falls squarely under the definition of a share issue or capital change announcement.
2021-05-11 English
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement regarding a capital increase resulting from the exercise of employee warrants. It details the number of shares issued, the subscription prices, and the impact on the total share capital. This falls under the category of share issues and capital changes. While it mentions an attachment, the text itself provides the full details of the capital change, making it a primary announcement rather than just a notification of a report publication.
2021-05-11 English
6-K
Foreign Filer Report
2021-05-10 English
Transactions in connection with share buy-back program
Transaction in Own Shares Classification · 100% confidence The document is a detailed appendix listing individual share buyback transactions (volume, price, venue, and timestamp) for the company Genmab over a specific period (May 3-7, 2021). This is a standard disclosure document for a share repurchase program. According to the provided filing definitions, 'Transaction in Own Shares' (POS) is the correct category for reports detailing the company buying back its own shares.
2021-05-10 English
Transactions in connection with share buy-back program
Transaction in Own Shares Classification · 100% confidence The document is a company announcement detailing specific transactions executed under a share buy-back program. It provides a table of share purchases, the total number of shares held as treasury shares, and references the regulatory framework (MAR/Safe Harbour). While it mentions attachments, the text itself contains the core data regarding the share buy-back activity, which aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2021-05-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.